Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 582.1 Crore for the first quarter ended on 30th June, 2020, as against INR 513.3 Crore for the same period last year, reflecting an increase of 13.4%.
The net profit for the period, on a consolidated basis, was INR 122.1 Crores as against INR 142.8 Crore same period last year, showing a decline of about 14.5%.
Increase in revenue was driven primarily by exports formulations business. During the quarter, the company faced margins pressure on both domestic and international formulations. In spite of lower margins during the first quarter, the company is confident of its business for remaining part of the financial year based on the order book and earnings outlook. The company expects a growth of over 25% in its earnings for FY2020-21 compared to prior year.
Contact:
Tel: +91-40-2354 7532
Web: www.natcopharma.com
(C) 2020 Electronic News Publishing, source ENP Newswire